Guest column
Embracing the present and owning the future in clinical trial execution
2018 was a pivotal year for the pharmaceutical industry and the execution of clinical trials.
Archives for December 13, 2018
SGS invests €3.5m in its French bioanalytical site
This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.
Infographic: Unifying clinical operations
CROs are taking steps to improve study start-up as collaboration with sites and sponsors continues to be a challenge, one which a unified clinical operations model aims to address.
CROs lead adoption of purpose-built clinical applications: Report
CROs are upping investment in modern eClinical solutions – a market expected to reach beyond $13bn by 2024.
Indivior succeeds in putting Suboxone generic on hold again
Indivior’s patent litigation with Dr. Reddy’s over Suboxone film continues after the company announced its preliminary injunction will stay in place.
Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
Scope’s report finds biologics likely to be protected from severe biosimilar erosion but sees warning signs for the generics industry.
Biorasi closes PE deal, next stage to be ‘vastly different’ as CRO plans scale-up
Biorasi plans to scale several aspects of its global CRO business following a PE investment – and while it does not plan to “buy size,” smaller strategic acquisitions are not out of the question, says company executive.
Smithers Avanza: New lab to support all phases of biotherapeutics development
Smithers Avanza’s Bioanalytical Services division is adding 18,500 square feet of laboratory space in New Jersey to support the development of biotherapeutics.
US farm bill a boon for pharma?
If approved by President Trump, the five-year farm bill – which removes hemp from the federal controlled substance list – could help advance cannabinoid R&D, says Nexien Biopharma.
bioProcessUK Conference
Is big pharma invested in small molecules? An ethical question
Large pharma has ‘a duty to society’ to work in both the small and large molecule space, according to outgoing GSK executive, Dave Tudor.